These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 16080556)

  • 1. Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer.
    Czejka M; Schueller J; Hauer K; Ostermann E
    Anticancer Res; 2005; 25(4):2985-90. PubMed ID: 16080556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
    Farkouh A; Scheithauer W; Buchner P; Georgopoulos A; Schueller J; Gruenberger B; Czejka M
    Anticancer Res; 2014 Jul; 34(7):3669-73. PubMed ID: 24982385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab.
    Ettlinger DE; Mitterhauser M; Wadsak W; Ostermann E; Farkouh A; Schueller J; Czejka M
    Anticancer Res; 2006; 26(2B):1337-41. PubMed ID: 16619542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.
    Rudek MA; Dasari A; Laheru D; He P; Jin R; Walker R; Taylor GE; Jimeno A; Donehower RC; Hidalgo M; Messersmith WA; Purcell WT
    J Clin Pharmacol; 2016 Aug; 56(8):966-73. PubMed ID: 26632033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
    Horita Y; Yamada Y; Hirashima Y; Kato K; Nakajima T; Hamaguchi T; Shimada Y
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):467-71. PubMed ID: 19554330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
    Choi CK; Chan RT; Tung SY; Lui L; Siu S; Au GK; Ho JW; Law WL
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):168-75. PubMed ID: 18155454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
    Goel S; Desai K; Karri S; Gollamudi R; Chaudhary I; Bulgaru A; Kaubisch A; Goldberg G; Einstein M; Camacho F; Baker S; Mani S
    Invest New Drugs; 2007 Jun; 25(3):237-45. PubMed ID: 17195945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].
    Yu BM; Wu WQ
    Zhonghua Wai Ke Za Zhi; 2005 May; 43(9):557-60. PubMed ID: 15938923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
    Czejka M; Schueller J; Farkouh A; Gruenberger B; Scheithauer W
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):613-9. PubMed ID: 20495919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
    Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine/irinotecan combination regimens in colorectal cancer.
    Kerr DJ
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):27-9. PubMed ID: 12014865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
    Delord JP; Pierga JY; Dieras V; Bertheault-Cvitkovic F; Turpin FL; Lokiec F; Lochon I; Chatelut E; Canal P; Guimbaud R; Mery-Mignard D; Cornen X; Mouri Z; Bugat R
    Br J Cancer; 2005 Mar; 92(5):820-6. PubMed ID: 15756252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; Semiond D; deJonge MJ; Eskens FA; ter Steeg J; Selleslach J; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    J Clin Oncol; 2005 Feb; 23(4):889-98. PubMed ID: 15681535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
    Kim TW; Kang WK; Chang HM; Park JO; Ryoo BY; Ahn JS; Zang DY; Lee KH; Kang YK; Kim SR; Kim HK;
    Acta Oncol; 2005; 44(3):230-5. PubMed ID: 16076694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
    Schreiber V; Kitzmueller M; Poxhofer M; Gintersdorfer S; Neudorfer C; Lichtneckert M; Dittrich C; Czejka M
    Anticancer Res; 2014 Jul; 34(7):3371-6. PubMed ID: 24982342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer.
    Czejka M; Kiss A; Koessner C; Terkola R; Ettlinger D; Schueller J
    Anticancer Res; 2011 Oct; 31(10):3573-8. PubMed ID: 21965780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
    Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
    Kerr D
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):12-5. PubMed ID: 12520634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.